Fresh Tracks Therapeutics reports GAAP EPS of -$2.07, revenue of $0.49M

  • Fresh Tracks Therapeutics press release (NASDAQ:FRTX): Q3 GAAP EPS of -$2.07.
  • Revenue of $0.49M (+276.9% Y/Y).
  • The company reported cash and cash equivalents of $11.3M as of Sep. 30, 2022, compared to $26.9M as of Dec. 31, 2021.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.